Will Puma Biotechnology, Inc. (PBYI) Crush EPS Estimates Again?
At present, the stock is 3.46% separated from the 52 week high and 181.15% from the low.
Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Down in the future. Short interest represents almost one-third of PBYI’s total available float, or about eight sessions’ worth of pent-up buying demand, at the biotech’s average pace of trading.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a yearly average return of -5.0% and a 37% success rate. As per Tuesday, May 23, the company rating was maintained by Stifel Nicolaus.
Puma Biotechnology (NYSE:PBYI) last released its earnings results on Wednesday, May 10th. Finally, Credit Suisse Group AG reaffirmed an “outperform” rating and set a $58.00 price target on shares of Puma Biotechnology in a research report on Tuesday, April 18th. Citigroup Inc reaffirmed a “buy” rating and set a $88.00 price target on shares of Puma Biotechnology in a research report on Monday. As per Wednesday, August 12, the company rating was downgraded by Barclays Capital.
Security Capital Research & Management Inc decreased Rlj Lodging Tr (RLJ) stake by 94.91% reported in 2016Q4 SEC filing.
Recent action on shares of Perion Network Ltd. (NASDAQ:PERI) lands the stock on today’s most volatile list. Over the past month the firm’s stock is 89.50%, 183.28% for the last quarter, 94.84% for the past six-months and 377.01% for the previous year. Pbf Energy Inc Cl A now has $2.27B valuation. UBS Asset Management Americas Inc. now owns 12,891 shares of the biopharmaceutical company’s stock worth $864,000 after buying an additional 300 shares during the last quarter. Sivik Glob Limited Co reported 30,000 shares. (NASDAQ:WFM) has risen 16.62% since May 24, 2016 and is uptrending. It has underperformed by 37.54% the S&P500.
Investors sentiment decreased to 1 in Q4 2016. Stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 4 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating.
Currently, the market capitalization of Puma Biotechnology, Inc. 22 funds opened positions while 53 raised stakes. State Street has 1.95 million shares. Puma Biotechnology Inc has a 52 week low of $27.64 and a 52 week high of $73.27. Moreover, Vanguard Grp Inc has 0% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 2.33M shares. Price T Rowe Assoc Md owns 678,435 shares. Partner Mngmt Lp owns 18,293 shares or 0.74% of their U.S. portfolio. BlackRock Inc. boosted its stake in Puma Biotechnology by 189.0% in the third quarter. Paradigm Asset Ltd Company accumulated 4,300 shares. Citigroup Inc, a New York-based fund reported 206,874 shares. D E Shaw And Company Inc reported 9,133 shares. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/05/25/puma-biotechnology-inc-pbyi-upgraded-to-buy-by-zacks-investment-research.html. $76,208 worth of Puma Biotechnology Inc (NASDAQ:PBYI) was sold by CHARNAS ROBERT on Friday, January 20. 106.04 million shares or 5.79% more from 100.23 million shares in 2016Q3 were reported. 796 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Franklin Street Advisors Inc. D E Shaw & Com owns 9,133 shares or 0% of their USA portfolio.
Since January 20, 2017, it had 0 insider purchases, and 6 sales for $690,596 activity. EYLER CHARLES R sold $27,253 worth of stock. American Group has invested 0% in Puma Biotechnology Inc (NASDAQ:PBYI). On Friday, January 20 the insider Lo Steven sold $76,108.
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. (NASDAQ:SORL)’s market cap, the total dollar value of all of their outstanding shares, is 155.29m. It now has negative earnings.